205 results on '"Kudo, Masatoshi"'
Search Results
2. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
3. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
4. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
5. Treatment of portal hypertension in patients with HCC in the era of Baveno VII
6. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study
7. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
8. Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel.
9. Histological diagnosis and grading of pancreatic neuroendocrine tumor by endoscopic ultrasound-guided fine needle biopsy using a 25-gauge needle with a core trap: A multicenter prospective trial
10. Reply to: “Evidence and choice: The BCLC vision for tailoring clinical decision-making”
11. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
12. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection
13. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
14. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
15. Breakthroughs in Hepatocellular Carcinoma Therapies.
16. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
17. THU-471-YI From randomised clinical trials to clinical practice: a systematic reviewand meta-analysis of real-word data on atezolizumab plus bevacizumab for advanced hepatocellular carcinoma
18. SAT-495 Real-World Data of Hepatocellular Carcinoma from 9 Asia-Pacific Countries (The INSIGHT Cohort): Overall Survival associated with choice of first therapy, number of lines of treatment and distance to hospital
19. OS-112-YI Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapybased systemic therapy
20. OS-078-YI Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
21. GS-005 mRECIST outcomes in EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization plus durvalumab with/without bevacizumab in participants with embolization-eligible hepatocellular carcinoma
22. Indigo naturalis as a promising novel treatment for type 2 autoimmune pancreatitis
23. Can the biliary enhancement of Gd-EOB-DTPA predict the degree of liver function?
24. Endoscopic Ultrasound-Guided Neurolysis in Pancreatic Cancer
25. Endoscopic Ultrasonography-Guided Biliary Drainage: Evaluation of a Choledochoduodenostomy Technique
26. Endoscopic Ultrasonography and Contrast-Enhanced Endoscopic Ultrasonography
27. Involvement of Angiotensin II and Reactive Oxygen Species in Pancreatic Fibrosis
28. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
29. THU-134 - Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction
30. THU-145 - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
31. THU-143 - Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients
32. THU-125 - Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the RATIONALE-301 study
33. THU-115 - Impact of baseline liver function on overall survival (OS) and safety in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS): results from the RATIONALE-301 study
34. THU-116 - The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab
35. FRI-300 - Development, clinical validation and implementation of a novel algorithmic score (GAAD) for the detection of early-stage hepatocellular carcinoma
36. GS-011 - IMbrave050: Efficacy, safety and patient-reported outcomes (PROs) for adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in hepatocellular carcinoma (HCC) patients at high risk of disease recurrence after resection or ablation
37. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
38. SAT597 - A comparative analysis of Elecsys GALAD and Elecsys GAAD score to detect early-stage hepatocellular carcinoma in an international cohort
39. Cost-Effectiveness of Lenvatinib in the Treatment of Patients With Unresectable Hepatocellular Carcinomas in Japan: An Analysis Using Data From Japanese Patients in the REFLECT Trial.
40. Preface
41. Improved detection of liver metastasis using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video).
42. Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan.
43. Severe Immune-Related Hepatitis Treated With Plasma Exchange.
44. A positive cytokine/chemokine feedback loop establishes plasmacytoid dendritic cell-driven autoimmune pancreatitis in IgG4-related disease.
45. A MULTICENTER PROSPECTIVE VALIDATION STUDY ON SELECTIVE ENDOSCOPIC RESECTION OF SESSILE SERRATED LESIONS USING MAGNIFYING COLONOSCOPY IN CLINICAL PRACTICE.
46. Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552]
47. Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer.
48. Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures.
49. PS-136-Can lenvatinib meet clinical needs of patients with unresectable hepatocellular carcinoma? Multicenter analysis
50. GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.